Clinical Trials Logo

Colitis, Ulcerative clinical trials

View clinical trials related to Colitis, Ulcerative.

Filter by:

NCT ID: NCT05202990 Not yet recruiting - Clinical trials for Pediatric Ulcerative Colitis in Remission

Oral Fecal Microbiota Transplantation in Pediatric Ulcerative Colitis

T-FORE
Start date: March 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate whether FMT by frozen stool capsules in pediatric UC patients in remission after corticosteroid treatment, can modify their dysbiotic gut microbiota by increasing the richness of their microbiota at 6 months.

NCT ID: NCT05190484 Not yet recruiting - Clinical trials for Rheumatoid Arthritis

bIosimilar of aDalimumab, an European evAluation

IDEA
Start date: April 30, 2022
Phase:
Study type: Observational

The study objective is aimed to describe all country, site, investigator and patient variables that lead to treatment persistence for at least 12 months among patients with rheumatologic and intestinal chronic inflammatory diseases who were switched to FK adalimumab, in order to develop a model to predict persistence at 12 months.

NCT ID: NCT05117749 Not yet recruiting - Ulcerative Colitis Clinical Trials

Saffron and Ulcerative Colitis

Start date: May 2023
Phase: Phase 2
Study type: Interventional

IBD is a chronic disease with two major types of Crohn's Disease (CD) and Ulcerative Colitis (UC). Nowadays, synthetic drugs and monoclonal antibodies are the most common types of drugs used for IBD management. However, due to their side effects and the high relapse rate, many researchers are looking for plant-derived products to manage the disease. Saffron, Crocus sativus L., is widely used as spice and medicine with anti-obesity, anticonvulsant, anti-hyperlipidemic, anti-tumor, antioxidant, and anti-inflammatory properties. Besides, there is evidence of the favorable effects of saffron on the gut microbiome. The main aim of this proposal is to evaluate the effect of saffron as a complementary supplement or add-on therapy in combination with current therapeutic agents in patients with mild and moderate UC.

NCT ID: NCT05112263 Not yet recruiting - Ulcerative Colitis Clinical Trials

Tofacitinib Versus Cyclosporine for Steroid Refractory Acute Severe Ulcerative Colitis

TOCASU
Start date: July 1, 2023
Phase: N/A
Study type: Interventional

This randomised trial plans to compare oral tofacitinib with intravenous cyclosporine in patients with acute severe ulcerative colitis who have failed to respond to intravenous steroids

NCT ID: NCT04999241 Not yet recruiting - Ulcerative Colitis Clinical Trials

Combined Application of EEN in the Induction of Remission in PUC

Start date: March 1, 2024
Phase: Phase 4
Study type: Interventional

The role of exclusive enteral nutrition (EEN) in the induction of remission in pediatric patients with Crohn's disease had been well documented. But the role of EEN in children with Ulcerative Colitis (UC) was not clear. In this study, EEN will be combined with corticosteroids or infliximab in the induction of remission in pediatric UC patients with moderate to severe disease activity. The mucosal healing rate at week12 will be compared between the two groups (combine with EEN group VS non-combine group).

NCT ID: NCT04939025 Not yet recruiting - Ulcerative Colitis Clinical Trials

Multi-interventional Program to Reduce Chronic Ileoanal Pouch Leaks in UC

MIRACLE
Start date: July 1, 2021
Phase: N/A
Study type: Interventional

The objective of this quality improvement project is to increase the one year anastomotic integrity rate in patients having had completion proctectomy and pouch reconstruction for Ulcerative Colitis by the routine and quality controlled implementation of a multi-interventional program thereby improving long-term pouch function and survival.

NCT ID: NCT04926103 Not yet recruiting - Clinical trials for Ulcerative Colitis Flare

Screening Donors, Fecal Microbiota Transplant Program in Ulcerative Colitis

FUEL
Start date: July 1, 2022
Phase: N/A
Study type: Interventional

The investigators intend to screen for new donors, given that there may a donor effect (PubMed ID: 25857665), with some donors not inducing remission in any patient whilst others inducing remission in 20-40% of cases. It is important to give UC patients participating in RCTs stool that has been demonstrated to be effective in some patients. We therefore propose to conduct an open label study in patients with active UC to ensure new donors are effective at inducing remission in some patients. Patients that have FMT will relapse within 18 months (PubMed ID: 25857665) although further FMT therapy induces remission so it is possible that maintenance FMT will result in long term remission, but this needs evaluation. We will therefore follow UC patients that have responded to FMT long term in this open label study.

NCT ID: NCT04919252 Not yet recruiting - Clinical trials for Crohn's Disease and Ulcerative Colitis

Efficacy and Safety of Vedolizumab in Biologic-naïve Korean Patients With Moderate to Severe Inflammatory Bowel Disease

VEDOKO-IIT
Start date: June 1, 2021
Phase: Phase 3
Study type: Interventional

If subjects voluntarily consent to participation in the study, those who are finally determined to be eligible for the study after whether all of the inclusion criteria and none of the exclusion criteria are met is checked will receive the study drug. Efficacy and safety will be evaluated at baseline, baseline, 2 weeks, 6 weeks, 14 weeks, 22 weeks, 30 weeks, 38 weeks, 46 weeks, and 54 weeks.

NCT ID: NCT04882566 Not yet recruiting - Ulcerative Colitis Clinical Trials

Assessment of Nutritional Knowledge in Patients With Inflammatory Bowel Disease

Start date: August 2021
Phase:
Study type: Observational

Patients with inflammatory bowel disease (IBD) are increasingly becoming interested in nonpharmacologic approaches to their disease. One of the most frequently asked questions of IBD patients is what they should eat. The role of diet has become very important in the prevention and treatment of IBD. Although there is a general lack of rigorous scientific evidence that demonstrates which diet is best for certain patients, several diets have become popular. Aim of the Work To assess IBD patients' knowledge about the role of nutrition in the management of their Inflammatory Bowel Disease and the dietary beliefs, behaviors, and daily dietary practices in adult IBD patients that they make to avoid exacerbation of disease symptoms or to gain more control of bowel symptoms, keeping in mind our traditional and oriental food and food habits in Egypt. Also to evaluate the role of one of the most common dietary regimens; the Paleolithic diet in active mild or moderate inflammatory bowel disease.

NCT ID: NCT04818788 Not yet recruiting - Ulcerative Colitis Clinical Trials

Hematological Indices and Fecal Calprotectin Predict Histological Remission in Ulcerative Colitis

Start date: April 1, 2021
Phase:
Study type: Observational

Investigators aimed at investigating the prediction ability of faecal calprotectin to predict mucosal healing and histological remission in ulcerative colitis patients receiving biological therapy Investigators aimed to evaluate the prediction ability of NLR, PLR and MLR to predict mucosal healing and histological remission in ulcerative colitis patients receiving biological therapy. Investigators evaluate the histological remission in ulcerative colitis patients receiving biological therapy in Assuit university hospital.